Document Detail


Systemic corticosteroids in chronic obstructive pulmonary disease: an overview of Cochrane systematic reviews.
MedLine Citation:
PMID:  16962307     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chronic obstructive pulmonary disease (COPD) is characterized by symptoms of cough, sputum and breathlessness, which become worse during acute exacerbations. The airway inflammation associated with COPD has led to trials of the effect of systemic corticosteroids in COPD assessed in two Cochrane systematic reviews. In stable COPD, compared with placebo, oral corticosteroid treatment increased mean FEV(1) by 53 ml and mean 12-min walking distance by 29 m, but at an increased risk of any drug-related adverse event (OR 7.8). In acute exacerbations, oral corticosteroid treatment decreased the chance of treatment failure (OR 0.48), improved mean FEV(1) at 72 h by 140 ml and improved arterial blood gases, but increased the risk of drug-related adverse events (OR 2.3). Thus, treatment of stable and acute exacerbations of COPD with systemic corticosteroids results in statistically significant average benefits, but at an increased risk of adverse events. In stable COPD, there is little support for the use of systemic corticosteroid treatment, as data on long-term outcomes are lacking. For acute exacerbations, the evidence to support the use of systemic corticosteroids is stronger, but further research is required to define the optimum dose, route and duration.
Authors:
Richard Wood-Baker; Julia Walters; E Haydn Walters
Related Documents :
4003917 - Effect of dosing schedule on efficacy of beclomethasone dipropionate aerosol in chronic...
19729427 - Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option.
22686127 - Comparison of acrylic and titanium cranioplasty(#).
10225757 - Plasma exchange versus intravenous immunoglobulin for guillain-barré syndrome.
9873287 - Dialysis time: what you prescribe is what you get? (wypiwyg).
23759667 - Effect of ribotype on all-cause mortality following clostridium difficile infection.
Publication Detail:
Type:  Journal Article; Review     Date:  2006-09-07
Journal Detail:
Title:  Respiratory medicine     Volume:  101     ISSN:  0954-6111     ISO Abbreviation:  Respir Med     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-02-09     Completed Date:  2007-04-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  371-7     Citation Subset:  IM    
Affiliation:
Cardiorespiratory Research Group, University of Tasmania, Private Bag 34, Hobart, Tasmania 7001, Australia. Richard.WoodBaker@utas.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adrenal Cortex Hormones / administration & dosage*,  adverse effects
Forced Expiratory Volume / physiology
Humans
Lung / physiopathology
Pulmonary Disease, Chronic Obstructive / drug therapy*,  physiopathology
Review Literature as Topic
Risk Factors
Treatment Failure
Walking / physiology
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cultural symbolism of fish and the psychotropic properties of omega-3 fatty acids.
Next Document:  The case for Survivin as mitotic regulator.